SAVING LIVES - IT'S IN OUR BLOOD.

©2016 CellMax Life - Confidential

SAVING LIVES - IT’S IN OUR BLOOD.


EARLY DETECTION IS THE BEST PREVENTION

CRC PROTECT™


2,000

5,000

8,000

11,000

14,000

17,000

Colorectal Cancer Incidence

- Health Ministry of Taiwan, 2016 Data

COLORECTAL CANCER INCREASINGDESPITE GOVERNMENT SCREENING EFFORTS


No symptoms

No family history

Scared of a colonoscopy

FOBT: Messy & Inaccurate

Time-consuming

30screening

uptake in Asia

%

CRC SCREENINGMOST PEOPLE NOT GETTING TESTED

For adults between 50 -65 years


Mutation causes abnormal cell growthUncontrolled cell growth leads to tumor formationGrowing tumor invades surrounding tissueSecondary tumors form in other parts of the body Cancer cells are able to travel through bloodstream

STAGES OF CANCER DEVELOPMENT

GROWTH AND METASTASIS


CRC: SLOW GROWINGPOLYP TO CANCER CAN TAKE 5 TO 15 YEARS

CANCER

Severe dysplasiaAdenomatous

Benign MALIGNANT

Adenocarcinoma

5-15 years


Stage I

Stage II

Stage III

Stage IV

15%

18%

35%

31%

- Taiwan Health Ministry, 2012 Data

MAJORITY DIAGNOSED LATE STAGE

AS TREATMENT COSTS INCREASE SIGNIFICANTLY


CANCER TYPE OF TEST SENSITIVITY* SPECIFICITY* FREQUENCY

COLORECTAL FOBT 5.4% to 19.8% 91.6% to 98%( ~50% in Taiwan)

Annually

CURRENT SCREENING IS NOT GOOD ENOUGHALL HAVE SEVERAL DISADVANTAGES

PROSTATE PSA 21% 91% 2-4 years

BREAST

CANCER Mammograms

68% (overall) 75% (overall)

1-2 years

38% to 58% (Asian; dense tissue)

45% to 65% (Asian; dense tissue)

LUNG CANCERNo available early

screening test n/a n/a n/a


Erythrocytes

Platelets

Reticulocytes

Neutrophils

Lymphocytes

Monocytes

Eosinophils

Basophils

CD34+ CellsnRBC

CECs

CD34+ CD38

EPCs

CTCs

Cells / mL

Challenge:

Find at early stage

CIRCULATING TUMOR CELLS: EXTREMELY RARE

Metastatic

lesions evolve

over time &

release CTCs

CTCs: Cells that

leave the primary

tumor & enter

bloodstream

CTCs may leave

the bloodstream

to form new

metastatic lesions


CTCs: KEY TO EARLY CANCER DETECTIONDIFFICULT TO DETECT IN EARLY STAGE CANCER

1PER BILLION BLOOD CELLS

Pre-Cancer

10 PER BILLION BLOOD CELLS

Early Stage Cancer

100sPER 10s OF BILLION BLOOD CELLS

Late Stage Cancer

OTHER TECHNOLOGIESCan only detect cancer cells in late stagesCRC PROTECT®


UNIQUE IP, DEVELOPED LEVERAGING YEARS OF RESEARCH

CMx PLATFORM™


Input

Proprietary antibody modification

yielding high-affinity pair-wise

binding

Biomimetic lipid bilayer maximizes

multivalent binding (clustering) of

cells

Patented, non-fouling surface

treatment reduces non-specific

adsorption

MICROFLUIDIC CHIPMAXIMIZES THE NUMBER OF INTERACTIONS FOR OPTIMAL CAPTURE EFFICIENCY…

CMx PLATFORM™PATENTED RARE-CELL DETECTION METHODOLOGY

Input

01.Patented microfluidic chip

Enumerate

07.RUN THE BLOOD

Airbinding event in the chip

CTC

AFFINITY BASED MICROFLUIDICS

reduces non-specific adsorption02.Gentle buffer flow flushes out non-specific binding blood cells in microfluidic

channel to further improve the purity of captured CTC04.

BIOMIMETIC SURFACE COATING

maximizes clustering of cells03.

ISOLATED CTC

binding of target cells to the membrane05.

RELEASING THE CTC

Air-bubble enabled cell release, maintaining cell

viability for further analysis

06.


ACCURATE ENUMERATIONSTAINING AND IMAGING

Proprietary software developed

for high resolution, high

throughput imaging


Total

Samples

304

Sensitivity 95%

Specificity 88%

PPV 94%

NPV 91%

1- Specificity

Se

nsitiv

ity

Br J Cancer. 2012 Apr 10; 106(8): 1424–1430.

CGMH Clinical Study CellMax

FOBT

CLINICAL STUDY RESULTS: CMx Platform

* Indeterminate results (11%) included in performance calculation


Early detection of cancer greatly

increases the chances for

successful treatment.


CRC PROTECT™

Simple blood test

Non-invasive, radiation-free, no side-effects

No messy stool tests or preparation

Highly accurate, clinically-proven detection

Breakthrough in the fight against cancer

Samples processed in a CAP accredited laboratory in Taipei


BLOOD TEST ANALYSIS REPORT CONSULT ROUTINE TEST

01 02 03 04 05

CRC PROTECTTM

We conduct extensive testing to find any traces of abnormal cells

Give 1 small sample of blood at the nearest test provider

You and your physician receive your test report within 1 week

Test regularly to maintain your good health!

Our clinical specialists will answer any questions you may have


What Are The Results For CRC Protect?

CRC ProtectHIGH-PROFILE MEDIA COVERAGE

2016


“We need a simple screening test

that can be administered

routinely, like a blood test, for

cancer screening.”Dr. Wen-Sy Tsai

CGMH, Taipei

“This blood test helps clinical

physicians like myself make

life-saving decisions as soon

as possible.”Dr. Hui-Ming Wang

CMUH, Taichung

Endorsed by leading Medical Specialists

https://youtu.be/gUDqhqBsn6g







“Early diagnosis through a simple,

non-invasive blood test”

“CellMax Life is Changing the

Rules for Cancer Screening”

Noticed by Global Media Leaders


“Disruptive technologies like

CellMax Life, bring early stage

cancer detection to the masses”

Silicon Valley Recognition

More Global Coverage


PUBLISHED IN PEER-REVIEWED PUBLICATIONS

Select Technical Publications Shown Here

May 2016

May 2016

Apr 2016

Jan 2016


PUBLISHED IN PEER-REVIEWED PUBLICATIONS

Select Technical Publications Shown Here

Mar 2016

Aug 2014

2013

2010


54 year old female

No prior history of cancer, no symptoms

CRC Protect® Test Date: Dec 9, ‘14

CRC-Protect® Test result: ABNORMAL

Colonoscopy Recommended

8 polyps detected; 1 adenoma

And one extremely relieved person

Annual FOBT Tests: Negative SAVING LIVESREAL CASE STUDY


Thank you!

SAVING LIVES - IT'S IN OUR BLOOD.

Documents

Transcript of SAVING LIVES - IT'S IN OUR BLOOD.